<p>針對百特國際公司（Baxter International Inc.）提起了一項集體訴訟，代表在 2022 年 2 月 23 日至 2025 年 7 月 30 日期間因涉嫌證券欺詐而遭受損失的投資者。訴狀指控百特發表虛假聲明，並隱瞞有關其 Novum LVP 產品的關鍵信息，該產品 reportedly 存在系統性缺陷，導致如輸液不足、輸液過量和完全不輸液等故障。這些問題 allegedly 使患者面臨嚴重傷害或死亡的風險。訴訟進一步聲稱，百特意識到多起設備故障、傷害和死亡事件，並且他們解決缺陷的努力不足，設計缺陷持續存在並繼續造成傷害。因此，客户被建議將 Novum LVP 停用的風險增加，百特也可能會停止新泵的銷售。該法律行動旨在追究百特對 Novum LVP 的安全性、有效性和銷售前景的 allegedly 誤導性陳述的責任。免責聲明：本新聞簡報由公共技術公司（Public Technologies，PUBT）使用生成性人工智能創建。雖然 PUBT 努力提供準確和及時的信息，但此 AI 生成的內容僅供參考，不應被解讀為財務、投資或法律建議。百特國際公司於 2025 年 12 月 4 日通過 ACCESS Newswire（參考 ID：1114625）發佈了用於生成本新聞簡報的原始內容，並對此信息承擔全部責任。© 版權 2025 - 公共技術公司（PUBT）</p>

<p>百特國際公司（Baxter International Inc.）面臨一起針對其 Novum LVP 產品的集體訴訟，指控其涉嫌證券欺詐。訴訟稱，百特作出了虛假陳述並隱瞞缺陷，導致產品故障，危及患者安全。該法律行動尋求對關於產品安全性和銷售前景的誤導性陳述追究責任</p>

<p>A class action lawsuit has been filed against Baxter International Inc. on behalf of investors who suffered losses due to alleged securities fraud between February 23, 2022, and July 30, 2025. The complaint alleges that Baxter made false statements and concealed critical information regarding its Novum LVP product, which reportedly suffered from systemic defects leading to malfunctions such as underinfusion, overinfusion, and complete non-delivery of fluids. These issues allegedly exposed patients to risks of serious injury or death. The lawsuit further claims that Baxter was aware of multiple device malfunctions, injuries, and deaths, and that their efforts to address the defects were inadequate, with design flaws persisting and continuing to cause harm. As a result, there was an increased risk that customers would be advised to take Novum LVPs out of service and that Baxter would halt new sales of the pumps. The legal action seeks to hold Baxter accountable for allegedly misleading statements about the safety, efficacy, and sales prospects of the Novum LVPs. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Baxter International Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1114625) on December 04, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)</p>
<div class="lb-trans"><p>針對百特國際公司（Baxter International Inc.）提起了一項集體訴訟，代表在 2022 年 2 月 23 日至 2025 年 7 月 30 日期間因涉嫌證券欺詐而遭受損失的投資者。訴狀指控百特發表虛假聲明，並隱瞞有關其 Novum LVP 產品的關鍵信息，該產品 reportedly 存在系統性缺陷，導致如輸液不足、輸液過量和完全不輸液等故障。這些問題 allegedly 使患者面臨嚴重傷害或死亡的風險。訴訟進一步聲稱，百特意識到多起設備故障、傷害和死亡事件，並且他們解決缺陷的努力不足，設計缺陷持續存在並繼續造成傷害。因此，客户被建議將 Novum LVP 停用的風險增加，百特也可能會停止新泵的銷售。該法律行動旨在追究百特對 Novum LVP 的安全性、有效性和銷售前景的 allegedly 誤導性陳述的責任。免責聲明：本新聞簡報由公共技術公司（Public Technologies，PUBT）使用生成性人工智能創建。雖然 PUBT 努力提供準確和及時的信息，但此 AI 生成的內容僅供參考，不應被解讀為財務、投資或法律建議。百特國際公司於 2025 年 12 月 4 日通過 ACCESS Newswire（參考 ID：1114625）發佈了用於生成本新聞簡報的原始內容，並對此信息承擔全部責任。© 版權 2025 - 公共技術公司（PUBT）</p>
</div>

Baxter International 因涉嫌證券欺詐而面臨集體訴訟